In Vitro: Halofenozide (RH-0345) reduces both growth and development of oocytes in vitro.
In Vivo: After topical application of Halofenozide (RH-0345; 5 and 10 μg) on adult females, the highest dose (10 μg) reduces significantly the reproductive parameters scored: namely the oviposition period, the fecundity and the egg viability. Halofenozide at the two doses tested (5 and 10 μg) causes smaller eggs with a decrease in length, width and volume.